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Abstract
In areas co-endemic for loiasis and onchocerciasis, the classic Community-Directed Treatment
using ivermectin (Mectizan®) must be adapted as additional program activities, better
communication and tighter control of ivermectin stocks are required to minimize risk and manage
serious adverse events following ivermectin treatment in patients co-infected with Loa loa. The
importance of these serious adverse events on community participation in onchocerciasis control
efforts has not been adequately studied. Program implementers do not as of yet fully understand
the psychological impact of serious adverse events on communities and therefore have not
designed communication strategies that adequately address the real concerns of community
members. It is clear, however, that along with an effective case detection and management strategy,
a reinforced communication strategy will be required to motivate at least 65% of the total
population in onchocerciasis and loiasis co-endemic areas to participate in the treatment program
and to take ivermectin over an extended period. This strategy must be based on research
undertaken at the community level in order to address the concerns, fears and issues associated
with adverse events due to ivermectin – to ensure that communities believe that the benefits of
taking ivermectin outweigh the risks. In addition to an overall increase in the time required to
sustain onchocerciasis control programs in co-endemic areas, each aspect of the reinforced
program and communication strategy – rapid epidemiological assessments, materials development,
training, advocacy, community sensitization and mobilization, case management and counselling,
supervision, monitoring and evaluation will require additional resources and support from all
stakeholders concerned.
Review
Introduction: How serious adverse events affect 
implementation of community-directed treatment with 
ivermectin
The issue of serious adverse events or side effects (SAEs)
due to ivermectin in areas co-endemic for loiasis has been
known for some time [1,2]. It was not until 1999, how-
ever, when the Center Province of Cameroon experienced
a large number of cases with coma (23) and 3 deaths [3],
that a more intensive effort was enlisted (i.e. Tours, France
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Meeting in October 1999 and 9th Technical Consultative
Committee (TCC9) meeting in March 2000) [4] to
develop a plan to manage SAEs, including planning of an
effective distribution strategy, more intensive supervision
and surveillance of SAEs and more intensive and targeted
information, education and communication (IEC)
activities.
With better surveillance, other provinces of Cameroon
and other countries (e.g. Sudan) are also reporting more
SAE cases in areas co-endemic with loiasis and onchocer-
ciasis. These co-endemic areas operate their programs
with a unique challenge to manage all adverse side effects
adequately, to maintain the cost per treatment at an
acceptable level and to achieve and maintain a treatment
coverage rate of at least 65% of the total population in
order to adequately diminish transmission among the
population and eliminate onchocerciasis as a public
health problem and socio-economic importance [5–9].
This is not an easy undertaking. Because of the fear caused
by serious adverse events [3,10–12], a reinforced strategy
is required to motivate communities to participate in
community-directed treatment with ivermectin (CDTI)
and to take ivermectin. A review of several of the inde-
pendent African Programme for Onchocerciasis Control
(APOC) monitoring reports from 1999–2001 docu-
mented that mild and serious side effects were neither
recorded nor reported in many projects, and in Cam-
eroon, health education was not adequate to allay fears
and misconceptions of community members about side
effects. In the report of one of the CDTI Projects in the
South West of Cameroon [12], the high rate of refusals
(27.7%) among those eligible for treatment was closely
linked to a high level of scepticism, doubt and pessimism
among community members and the absence of a strong
sensitization and mobilization effort. Likewise, an evalu-
ation of the implementation of TCC9/Mectizan® Expert
Committee guidelines in areas of Cameroon co-endemic
for onchocerciasis and loiasis undertaken by APOC and
the TCC in October 2000 [11] found that, in general, com-
munities did not have enough information on side effects
to allay their fears. In the presence of SAEs, rumours and
incomplete information, some community members
acknowledged fear associated with even minor side effects
and were understandably reticent to take ivermectin (Fig-
ure 1).
The presence of SAEs requires increased and improved
health education and communication activities at the
community and family level on early "warning" signs of
SAEs, additional training and increased supervision at all
levels, and additional program activities not necessary in
areas where loiasis is absent [4,11]. The presence of SAEs
not only increases the cost of implementing CDTI, but
changes the very nature of the APOC CDTI strategy and in
particular requires health personnel and communities to
work together much more closely to manage the problems
at the community level.
Special issues to consider when implementing CDTI in the 
presence of Serious Adverse Events
Many articles reviewed [13–20] provide evidence on the
critical importance of community participation in all
aspects of CDTI – appropriate and targeted health educa-
tion (in several cases to allay fear of side effects), commu-
nity sensitization and mobilization to motivate
participation, and the selection and training of commu-
nity distributors of ivermectin (CDD) by the community
for achieving and sustaining high treatment coverage lev-
els. None of these articles, with the exception of TCC
guidelines and Cameroon-based information
[3,10,11,21–24], however, discussed the particular chal-
lenges faced by CDTI programs in co-endemic areas due to
the presence of SAEs. As a result of the high number of
SAE cases experienced in Cameroon during 1999, addi-
tional research was carried out in an attempt to better
understand the issues related to SAE management. The
Centre Pasteur of Cameroon study [21] further defined
the parameters of SAEs (prevalence, timing of onset, risk
factors), which allowed program recommendations to be
made. They concluded that more training, more sensitiza-
tion and more supervision are necessary to better manage
SAE cases so that the prognosis on cases is improved.
Using this information, evaluation findings [11] and les-
sons learned over 5 years of CDTI implementation in a
loiasis and onchocerciasis co-endemic area of Cameroon,
Vicious cycle of SAEs and low coverage caused by increased  fear of taking ivermectin Figure 1
Vicious cycle of SAEs and low coverage caused by increased 
fear of taking ivermectin.
Presence of
SAEs in
community
Fear due
to SAEs
Reticence
of people
to take
ivermectin
Low
treatment
coverage
Rumors
about
ivermectinFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S10
Page 3 of 9
(page number not for citation purposes)
some of the special programmatic issues to consider when
developing the distribution and communication strategy
are outlined below. The strategy will necessarily be differ-
ent between areas with SAEs due to ivermectin and those
areas without this problem because of the medicalization
of the CDTI program and the fear associated with presence
of SAEs at the community level.
Program-related issues in the presence of serious adverse 
events
Identification of onchocerciasis-endemic communities
In order to minimize risk of serious adverse events in loi-
asis-endemic areas, mass treatment with ivermectin is
undertaken in only the onchocerciasis hyper-endemic and
meso-endemic villages in accordance with the APOC's
TCC guidelines. The villages are identified based on a
rapid epidemiological assessment (REA) at the outset of
the CDTI project.
Without adequate resources, careful planning, effective
training or close supervision the categorization of villages
can be inaccurate. Occasionally, some at-risk villages are
excluded from the survey (and mass treatment) because
they are inaccessible. It can also happen that hypo-
endemic villages are included in mass treatment. Commu-
nity sensitization prior to the survey is important to max-
imize participation [25] in order to give each eligible
person an equal chance of inclusion in the survey. Since
the survey is conducted by health personnel who do not
always ensure the randomness of the sampling in each vil-
lage, however, even with optimal community participa-
tion the representativeness of the results can be
questionable. Adequate training for the REA therefore is
an important element to ensure that only hyper- and
meso-endemic villages are included in mass treatment in
order to minimize unnecessary risk of SAEs to people liv-
ing in onchocerciasis hypo-endemic areas.
It can happen that hypo-endemic villages are found close
to meso-endemic villages, which can pose a problem dur-
ing treatment, as hypo-endemic villagers do not often
fully understand their exclusion and may seek treatment
in neighbouring villages. Careful communication is
needed to rectify these potential problems so that those
people living in hypo-endemic villages, but who have
onchocerciasis, seek and receive treatment at a referral
hospital and not from a CDD. In addition, considering
that the endemicity of onchocerciasis is not static due to
environmental related issues, the REA results should be
updated as the project evolves and adjustments made in
order to truly eliminate onchocerciasis as a public health
problem.
Planning
Planning and effective organization take on more impor-
tance when distribution needs to be more synchronized
from village to village in order to better control the distri-
bution of ivermectin to ensure proper surveillance of
SAEs. So that all SAE cases receive adequate attention and
care at each level, each district and each community must
abide by their action plan once developed, which should
include more frequent consultation meetings between
communities and MOH personnel, supervised commu-
nity selection of CDDs, updating of census figures, and a
specific plan for SAE management, training, sensitization,
distribution and supervision [23].
The decentralization of referral hospitals is important for
the recovery of SAE cases, in part, because patients who
are treated near their usual residence are more likely to be
assisted by family members in their nursing care. These
hospitals must have a well-trained team of professionals
as well as necessary medication and equipment to prop-
erly manage SAE cases. Communities need to be informed
of the designated referral hospital and be advised to go
there as trained staff, medication and equipment to prop-
erly manage SAE cases are not necessarily found at the
nearest hospital, which may be in an adjacent area not
involved in CDTI.
A major challenge is to ensure that all communities in co-
endemic areas where ivermectin is being distributed have
access to a referral hospital as some communities are
difficult to reach by road and may be more than 30 kms
from a referral hospital. On the other hand, although cit-
ies are generally near a referral hospital, distributing iver-
mectin in cities with their more transient population and
lack of cohesive community leadership, poses other prob-
lems in terms of selection of CDDs, taking an accurate
census, implementing a motivating communication strat-
egy to encourage participation in CDTI and surveillance of
the population post-treatment.
Training
Early recognition of SAEs is one of the key elements in
their effective management. SAE recognition, prevention,
referral, counselling, management and reporting must be
a primary focus of all training and retraining at all levels
(CDDs, nurses, doctors) [26–28]. Ensuring a high level of
CDD competence on recognition of early signs of SAEs is
critical. Another important issue to address during train-
ing is that CDDs should provide community members
with consistent, correct information on alcohol consump-
tion before and after ivermectin treatment. Contradictions
between information in manuals, health education mes-
sages and what the community believes to be true should
be highlighted and clarified. IEC supports can be used as
reminders on SAE information to help communityFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S10
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distributors. In addition, because of a relatively high turn-
over among government health staff, steps must be taken
to ensure that any new staff who arrive during distribution
receive adequate training.
In addition, a team of health personnel (at least 4 people)
at each referral hospital must be well trained on diagnosis
and management of cases so that all personnel who come
in contact with an SAE case have the necessary back-
ground, understanding and motivation to manage the
case properly. Interpersonal communication and counsel-
ling skills should also be taught so that hospital staff can
give appropriate and caring feedback to family members
[11]. The Ministry of Health and HKI in Cameroon have
drafted a guidebook for the management of SAEs that can
be reviewed and improved for wider use [29].
Selection of Community Distributors
Because of the increased knowledge and skills necessary to
pass on the additional information to community mem-
bers and to supervise post-treatment, the selection of the
CDD is highly critical and should be supervised by health
personnel after discussions with the community as to the
type of person needed to carry out the duties. The CDD
selected by the community must possess a minimal edu-
cational level, be stable, and be accepted by all in the com-
munity. This process is even more difficult in cities
because of the lack of community cohesiveness and
support.
Sensitization and Advocacy
Because SAE cases, and particularly poor management of
these cases, cause fear and breed rumors [3,10–12], dur-
ing the sensitization of communities an emphasis must be
placed on ensuring that IEC materials and sensitization
activities focus on identification and prompt referral of
SAEs at the community level. Providing information on
the reasons why side effects happen and their frequency
and prognosis is also important in stopping rumors and
allaying fears.
Counseling post-SAE may also serve to allay fears. The
development of a counseling guide to be used by key com-
munity leaders to provide support to SAE cases and their
families is underway, but will require additional training
of key community members.
Distribution
The need to minimize problems associated with poor rec-
ognition and management of SAEs necessitates that indi-
vidual communities have somewhat less control in the
organization of mass treatment campaigns. A joint distri-
bution strategy needs to be elaborated to better ensure
that treatment and post-treatment are adequately super-
vised by health personnel in each village [4]. Activities
must be synchronized in a health area so that health per-
sonnel are available and so that the ivermectin supply is
controlled. Elements of the strategy might be:
 Villages are grouped for scheduled treatment in a logical
order so that the nurse is available to supervise post-treat-
ment in each village as per TCC guidelines.
 The CDDs, with community leaders, organizes and pro-
motes the distribution time before hand and gives the
ivermectin at a central site in the village to reach the great-
est number of residents. Soon afterward, a mop-up can be
done by the CDD.
 The CDD watches each person swallow the ivermectin
and refuses to give any ivermectin to anyone for later con-
sumption by other family members not physically
present.
 The nurse collects all of the unused ivermectin within a
day after the distribution is completed in the village. The
control of ivermectin is critical in ensuring proper super-
vision of SAE cases. Training and monitoring tools are
needed. Guidelines on the management of ivermectin at
each level have been developed.
Identification, referral and care of SAE cases
Family members are usually the first to identify potential
SAE cases based on the information that they are provided
about potential adverse side effects due to ivermectin.
They must be adequately informed to contact the CDD in
their community, who in turn, must understand the
importance of timely referral of mild cases to the nurses
for treatment and immediate referral of serious cases to
the closest designated referral hospital.
The cost to treat adverse effects is an issue with commu-
nity members and a potential factor in low coverage as it
can discourage participation. In Cameroon, mild adverse
reactions to ivermectin are generally supported by the
patient and family, whereas the referral hospital takes
complete charge of all serious cases, paying directly for
diagnostic tests, medication and hospitalization. Poten-
tial problems exist as those people with minor side effects
often feel that they should be taken care of also. Addition-
ally, since only confirmed cases are free, some patients
delay going to the hospital because they are not sure if
their adverse health is due to ivermectin or not – as they
can not afford to pay for treatment if it turns out that their
illness is unrelated to ivermectin. For patients from hypo-
endemic areas, although the test for loa loa is required at
the hospital, neither the test, the consultation nor the
treatment is free. The cost information needs to be part of
the IEC message to avoid false rumors or confusion that
can discourage participation in CDTI [23].Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S10
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Supervision and reporting
There is a need for increased and improved supervision by
health personnel and CDDs in accordance with the TCC9
guidelines. In addition, follow-up by health personnel of
recovering patients after hospitalization should be under-
taken in communities [11,23]. Timely reporting and doc-
umentation must be strict. Unfortunately, the ability of
many personnel to supervise and report accurately is often
less than optimal due to the lack of skill, insufficient logis-
tics and poor motivation. Additional training and support
on how to effectively supervise is needed. Reporting pro-
cedures of potential and actual SAE cases must be dis-
cussed during training sessions as a critical element of
proper SAE management so that each SAE case can be ver-
ified by project staff and follow-up undertaken to make
sure hospitalized patients receive adequate care.
Communication-related issues in the presence of serious 
adverse events
From the above issues cited in each element of the pro-
gram plan and distribution strategy, it is clear that a rein-
forced, effective communication strategy including
sensitization and mobilization, training, advocacy and
health education – that is well designed and well imple-
mented – is critical to long-term onchocerciasis control in
the presence of SAEs. Many studies [30–37], in addition to
those already referenced, provide evidence as to the
importance of understanding community attitudes,
beliefs and perceptions in order to design communication
messages and materials that will better motivate participa-
tion in onchocerciasis control programs. Because most of
these studies have taken place in areas without SAEs, they
have not provided specific information related to commu-
nity attitudes or behaviours in the presence of SAEs. Most
of the communication and training strategies and materi-
als developed have therefore focused on increasing
knowledge about onchocerciasis and CDTI in order to
promote compliance among communities for long-term
ivermectin distribution. Methods to collect relevant
knowledge, attitude and practice (KAP) data at the com-
munity level are well known, yet few KAP surveys have
been done before strategy development in SAE areas.
APOC has likewise developed a strategy [38] that, if cor-
rectly implemented, will greatly assist countries to put in
place a more research-based, comprehensive advocacy
and health education plan – to date the strategy has not
been widely implemented.
Most of the available data on IEC issues related specifi-
cally to SAEs comes from Cameroon
[3,10,11,22,24,39,40], where the majority of reported
cases and fatalities due to ivermectin have occurred. In
areas co-endemic with onchocerciasis and loiasis, infor-
mation on adverse side effects has been included as part
of health education and training efforts [26–28,40,41].
The community sensitization activities have typically
been carried out by nurses and CDDs. How effective these
efforts have been in transmitting the information and
motivating behavior change is variable across projects
based on coverage statistics, but it is clear that there is still
considerable work to do before a comprehensive commu-
nication and training strategy is implemented that truly
addresses the issues related to motivating full participa-
tion in CDTI in co-endemic areas.
In 1996, HKI conducted a KAP study in 4 health districts
of Cameroon [40] from which a training guide [26] was
developed that included a section on proper management
of side effects. This guide was developed into a Regional
Training Guide [27] for health personnel and CDDs that
was adapted for use in Niger, Mali, Cameroon, Burkina
Faso, Nigeria and Tanzania. After the large number of
SAEs occurred in Okola in 1999, the Cameroon version
was revised and additional information on SAE manage-
ment [28] was added based on two community studies
[3,22] which showed a general lack of information about
CDTI and about SAEs. Key health education messages
related to side effects were elaborated. A section on How to
convince people to take ivermectin was included with
responses to common concerns. Although the documents
were well done, the messages do not seem to be adequate
in light of the increased number of SAE cases. The training
modules were well defined, yet at each level of the cascade
training, the skills and knowledge do not seem to translate
adequately into building community participation and
motivating people to take ivermectin. These training mod-
ules have been continually revised based on feedback
from users, but should be evaluated.
In December 1998 a workshop was held in Cameroon
[41] to review messages and materials used by various
projects and to decide on a uniform set of messages and
materials for the National Onchocerciasis Control Pro-
gram (NOCP). In one case, a KAP survey had been done
to elaborate the messages and materials (posters, book-
lets, songs) based on the program objectives. In a few
cases, information on the existence of SAEs was included
as part of the project's IEC messages and materials. In the
end, the standard set of messages and materials developed
by the NOCP was not completely based on community
level research and very little related to management of
SAEs was included. None of the materials underwent test-
ing before final production. In addition, a comprehensive
communication strategy was not developed to accompany
the agreed materials. Consequently, the messages have
not been motivating in loiasis-endemic areas and the
materials have not been well used by health personnel or
CDDs. Likewise, in 1998 APOC developed a manual
based in part on a multi-country study [20] that only
touched on issues related to SAEs. Consequently some ofFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S10
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the statements included in that manual [42], such as "the
medicine is without danger" are not valid in co-endemic
areas, and when told to community members can create
doubt about the program.
Evaluation data [11,12], along with findings from a KAP
survey [22] and three studies [3,10,21] done in co-
endemic areas of Cameroon, have allowed some progress
to be made in terms of defining a better, more targeted
communication and training strategy. The most recent
study [10] conducted by HKI at the end of the last 2001
CDTI campaign again reinforced the need for revised mes-
sages, more pertinent IEC materials based on community
data, and the development and implementation of a more
comprehensive communication strategy because the mes-
sages and strategy being used were not yet adequate to
motivate at least 65% participation in CDTI (Table 1).
Conclusions and Research Recommendations
It is clear that the presence of SAEs, even when they are
well managed, requires a reinforced approach to convince
people that the benefits of taking ivermectin outweighs
Table 1: Problems identified and recommendations made from studies to improve communication strategies in co-endemic areas
Problems Identified Recommendations made
Absence of a global IEC strategy. [10,24] Develop an overall communication strategy from community-based 
research. [10,24] The plan should include disseminating clear, consistent 
and complete tested messages to demystify SAEs, allay fears and 
motivate participation in CDTI via multiple, appropriate channels to 
reinforce messages from national to community level. [10,23]
Incomplete messages given in communities cause doubt and allowing 
rumours to continue [3,11,23] (i.e. SAEs emphasized without explaining 
cause and prognosis. CDDs don't inform people about potential side 
effects because they do not want to be seen as distributing a dangerous 
drug. [10]
SAE training, materials and messages include complete information – 
why side effects happen, how all medications can have side effects, what 
are particular side effects of ivermectin, how long side effects last, 
effectiveness of treatment of side effects, the system to take charge of 
side effects, the efficacy of ivermectin, and health problems associated 
with onchocerciasis. [3,10,11,21,23]
Mistrust of government enhances negative rumours related to SAEs and 
ivermectin. [23] Insufficient implication of administrative authorities in 
sensitisation activities. [24]
Have an official launching ceremony with health, traditional and 
administrative officials and media. [10,23] Conduct advocacy at the 
highest levels to reinforce messages given in the communities. [24]
Messages are not motivating to behaviour change – are not creating 
demand for ivermectin in communities and are not well enough crafted 
to vanquish fear of SAEs. [10,11] There is insufficient community 
involvement in developing the messages. [24]
Design messages based on KAP survey done in and with communities. 
[10,24] Message must appeal to the population at the physical, emotional 
and practical level so the risk and fear of SAEs is less important than the 
treatment for onchocerciasis. [23,38] Evaluate the communication 
strategy to know if the messages were motivating enough to change 
behavior. Apply lessons learned to continually improve the strategy and 
messages. Encourage the use of testimonials of villagers. Monitor villages 
to know if the messages are being heard and understood. [10]
Health personnel are not reinforcing CDD messages adequately: source 
is important on medical issues like SAEs. [10,11,23]
Systematize sensitization activities by nurses before, during and after the 
distribution. [10,22,23]
There is insufficient competence in communication techniques at all 
levels. [10,23,24]
Include practicum on communication techniques in nurse and CDD 
training. [10,23,24] Encourage a positive, caring attitude among CDDs 
and health personnel toward SAE cases. [11] Reinforce skills during 
supervision. [23]
Visual supports are not well understood without explanation, nor are 
they often used to give health education. [10,22] There are insufficient 
IEC materials related to SAEs for health professionals and communities. 
[11,22,24]
Develop IEC supports that motivate, are graphic and self-explanatory 
based on information from community research. Explain the content of 
supports during health education sessions. [10] Produce enough 
materials for wide distribution in villages. Finalize supports specifically 
for health professionals on SAE management. [10,11,22]
Communities are not adequately informed or implicated in management 
of SAEs. There is a lack of information at the village level. [3,10–12,21–
24]
Train CDDs and community leaders on SAEs, detection and referral. 
[11] Train church, school and social leaders to help sensitize the 
community and counsel SAE cases. [10,11,23] Train medical staff to 
counsel recovering SAE cases. [11] Sensitize communities before, 
during, and after distribution, including improved health education of 
families to understand the signs of alarm for SAEs and to know what to 
do about them. [3,11,21,23]
Absence of advocacy materials. [24] Develop an advocacy kit to target resources. [24]
Insufficient number of IEC experts. [24] Identify experts outside Onchocerciasis control program that could be 
tapped. [24]
Insufficient data on the relationship between SAEs and coverage. 
[11,23,24]
Conduct well-designed study to assess the relative importance of SAEs 
to coverage levels. [11,23,24]Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S10
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the risk. Increased and improved supervision, training,
and communication activities and skills are all needed to
allay the fears caused by actual side effects and by
rumours. Reducing fears will help to increase treatment
coverage, which will in turn reduce the number of SAEs
over time, which will increase participation in CDTI so
that onchocerciasis can be eliminated as a public health
problem (Figure 2).
So what is needed to more adequately address the pro-
gram and communication issues related to SAEs and to
better ensure the success of CDTI in co-endemic areas?
A study could be conducted to look at the reason why the
majority of reported cases and fatalities due to ivermectin
have occurred in Center Province of Cameroon. This phe-
nomenon is unclear and should be explored in further
depth. Is it due to biological or environmental factors, an
ineffective management of SAE cases as compared to other
countries or perhaps better surveillance and reporting in
Cameroon?
An operational research study should be conducted in co-
endemic areas to find out the comparative weight of vari-
ous factors on coverage, including the general lack of
information about CDTI, the lack of information specifi-
cally about SAEs, fear caused by the presence of SAEs, the
motivation of CDDs, ineffective SAE management, the
cost of SAE management to the family, and lack of con-
cern for onchocerciasis as an important personal or com-
munity health problem, among others factors. Taking
ivermectin at the population-level could be analyzed as a
cost-benefit issue to gain insight on the difficulty of full
participation over time. Furthermore, evaluations of CDTI
projects in co-endemic areas should be conducted to
assess and compare the additional costs associated with
implementing CDTI in co-endemic areas and the addi-
tional time that it will take before program activities can
be sustainable.
The existing training modules and actual training sessions
should be reviewed and revised as necessary based on a
thorough evaluation of their success in teaching skills and
motivating effective action at all levels. This could be con-
ducted by an expert trainer who could then make recom-
mendations for improvement and design an intensive
training-of-trainers skills workshop, (if warranted), to
enhance the transfer of information from one level to the
next.
Finally, well-designed qualitative research should be con-
ducted in communities affected by SAEs to identify their
real concerns, attitudes, beliefs, perceptions and practices
related to participation in CDTI. These findings can by
used to develop a comprehensive communication
strategy, coupled with the effective management of side
effects. The research can be used to design and test
messages that will motivate community members to
believe that the benefits of taking ivermectin are greater
than the risks associated with SAEs – that onchocerciasis
is a serious disease and its elimination is worth a long-
term community effort, that ivermectin is effective, that
adverse side effects can be recognized and effectively
treated, that the cost is not too high to the family, that no
one needs to die or be permanently disabled from taking
ivermectin, and that no one needlessly go blind because
of fear of SAEs.
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